Business Standard

Sunday, December 22, 2024 | 07:10 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Local pharma companies to challenge MNCs in pneumonia vaccine space

The Indian market is at present dominated by GlaxoSmithKline Pharma and Pfizer

Local pharma companies to challenge MNCs in pneumonia vaccine space
Premium

Sohini Das Mumbai
The duopoly of pneumonia vaccines in India is in for some shake-up soon, as homegrown players like Aurobindo Pharma, Cadila Healthcare (Zydus Cadila), and Serum Institute are readying their vaccine candidates. The Indian market is at present dominated by GlaxoSmithKline Pharma and Pfizer. 

India has the highest burden globally for pneumonia-related child deaths. In 2016, the number of pneumonia deaths among children under five was 158,176 in India, according to the Pneumonia and Diarrhoea Progress Report released in 2018-end by International Vaccine Access Centre (IVAC) at the Johns Hopkins Bloomberg School of Public Health. Over two-thirds of the global burden of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in